We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Molecular landscape and subtype-specific therapeutic response of nasopharyngeal carcinoma revealed by integrative pharmacogenomics.
- Authors
Ding, Ren-Bo; Chen, Ping; Rajendran, Barani Kumar; Lyu, Xueying; Wang, Haitao; Bao, Jiaolin; Zeng, Jianming; Hao, Wenhui; Sun, Heng; Wong, Ada Hang-Heng; Valecha, Monica Vishnu; Yang, Eun Ju; Su, Sek Man; Choi, Tak Kan; Liu, Shuiming; Chan, Kin Iong; Yang, Ling-Lin; Wu, Jingbo; Miao, Kai; Chen, Qiang
- Abstract
Nasopharyngeal carcinoma (NPC) is a malignant head and neck cancer type with high morbidity in Southeast Asia, however the pathogenic mechanism of this disease is poorly understood. Using integrative pharmacogenomics, we find that NPC subtypes maintain distinct molecular features, drug responsiveness, and graded radiation sensitivity. The epithelial carcinoma (EC) subtype is characterized by activations of microtubule polymerization and defective mitotic spindle checkpoint related genes, whereas sarcomatoid carcinoma (SC) and mixed sarcomatoid-epithelial carcinoma (MSEC) subtypes exhibit enriched epithelial-mesenchymal transition (EMT) and invasion promoting genes, which are well correlated with their morphological features. Furthermore, patient-derived organoid (PDO)-based drug test identifies potential subtype-specific treatment regimens, in that SC and MSEC subtypes are sensitive to microtubule inhibitors, whereas EC subtype is more responsive to EGFR inhibitors, which is synergistically enhanced by combining with radiotherapy. Through combinational chemoradiotherapy (CRT) screening, effective CRT regimens are also suggested for patients showing less sensitivity to radiation. Altogether, our study provides an example of applying integrative pharmacogenomics to establish a personalized precision oncology for NPC subtype-guided therapies. Nasopharyngeal carcinoma (NPC) is a malignant cancer type with high morbidity in Asia, and its current molecular classification is insufficient to predict therapy outcomes. Here the authors explore NPC subtype-specific response to therapy with a pharmacogenomics strategy integrating genomics and drug response of patient-derived organoids.
- Subjects
SOUTHEAST Asia; ASIA; NASOPHARYNX cancer; PHARMACOGENOMICS; HEAD &; neck cancer; SPINDLE apparatus; MICROTUBULES; EPITHELIAL-mesenchymal transition; EPIDERMAL growth factor receptors
- Publication
Nature Communications, 2021, Vol 12, Issue 1, p1
- ISSN
2041-1723
- Publication type
Article
- DOI
10.1038/s41467-021-23379-3